bristol myers food and drug administration news

Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.

MarketWatch · 16h

Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Benzinga.com · 13h

Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent value rights holders' payments.

U.S. News & World Report · 1d

Bristol Myers Faces Renewed, $6.7 Billion Lawsuit Over Delayed Cancer Drug

Business Insider · 13h

Bristol Myers receives positive CHMP opinion for repotrectinib

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended

4don MSN

Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

BioPharma Dive4d

AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

What's Going On With Bristol-Myers Squibb Shares Monday?

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

3don MSN

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

NBC 10 Philadelphia16d

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

Notably, the Food and Drug Administration approved Bristol Myers Squibb's highly anticipated schizophrenia drug Cobenfy during the quarter. It is the first novel type of treatment for the ...

Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

The Associated Press on MSN15d

A promising schizophrenia drug showed mixed results. What does that mean for patients?

In contrast to the weight gain seen with other schizophrenia drugs, people lost a few pounds while taking Cobenfy, made by ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results